Skip to main content
Year archive

Spexis AG — 2021 filings

All 20 regulatory filings released by Spexis AG (SPEX) in 2021, sourced directly from the official regulator.

20 Filings
2021 Period
2021 filings (20)
Filing Released Lang
Polyphor closes merger with EnBiotix and is renamed Spexis
Delisting Announcement
2021-12-30 English
Polyphor to inform about the financing of its merger partner EnBiotix
M&A Activity
2021-12-29 English
Polyphor and EnBiotix announce dosing of first patient in a first-in-human clinical trial of inhaled murepavadin
Legal Proceedings Report
2021-12-15 English
Polyphor shareholders approve all resolutions for the planned merger with EnBiotix at the Extraordinary General Meeting
AGM Information
2021-10-29 English
Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer in connection with planned Enbiotix Merger
Legal Proceedings Report
2021-10-15 English
Polyphor publishes invitation to Extraordinary General Meeting and announces financial results for the first half 2021
Regulatory Filings H1 2021
2021-09-27 English
Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by EnBiotix
M&A Activity
2021-09-10 English
Polyphor and EnBiotix announce signing of merger agreement and sale of Inhaled Murepavadin to EnBiotix
M&A Activity
2021-09-01 English
Polyphor provides final update on the Phase III FORTRESS study of balixafortide in patients with advanced HER2 negative breast cancer
Earnings Release Q3 2021
2021-08-03 English
Polyphor to extend period for its strategic evaluation by up to four weeks
Regulatory Filings
2021-07-30 English
Polyphor provides update on the future of the FORTRESS study of balixafortide and announces initial restructuring steps
Management Reports
2021-07-16 English
Polyphor provides update on the Phase III FORTRESS study of balixafortide in patients with advanced HER2 negative breast cancer
Regulatory Filings
2021-06-28 English
Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe Infections and the Potential Role of Balixafortide, a Selective CXCR4 Antagonist
Regulatory Filings
2021-06-08 English
Polyphor's balixafortide demonstrates consistent dual action anti-viral and anti-inflammatory activity in COVID-19 preclinical trials
Regulatory Filings
2021-06-01 English
Polyphor to present at the UBS Global Healthcare Virtual Conference
Report Publication Announcement
2021-05-18 English
Polyphor Annual General Meeting 2021
AGM Information
2021-04-06 English
Polyphor publishes invitation to Annual General Meeting 2021
AGM Information
2021-03-15 English
Polyphor announces financial results for the full-year 2020
Earnings Release FY 2020
2021-03-05 English
Polyphor to present full-year 2020 financial results on March 5
Report Publication Announcement
2021-02-26 English
Polyphor to take part in panel discussion on novel oncology targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Legal Proceedings Report
2021-01-05 English